Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire.
RedHill Biopharma Ltd. said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.
Access to new medicines and safety checks on existing treatments will be jeopardized if politicians pick a new home for Europe’s London-based drugs regulator that is unacceptable to staff, its executive director told Reuters.
Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.
Shiel Medial Laboratory will terminate 538 employees at a New Jersey facility following the company’s acquisition by Quest Diagnostics. The layoffs were announced one day after Quest’s acquisition was announced.
Celgene entered into a partnership to take on autoimmune diseases with two of New Jersey-based Nimbus Therapeutics’ preclinical therapeutics.
A seasonal flu vaccine that would be the world’s first to fight all types of the virus will be tested in a two-year study involving 2,000+ patients by Oxford researchers.
Allergan Plc was sued by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.
The U.S. FDA announced measures designed to speed to market generic versions of complex drugs in an effort to address the rising costs of pharmaceuticals.
U.S. scientists Jeffrey Hall, Michael Rosbash and Michael Young won the 2017 Nobel prize for medicine for unraveling molecular mechanisms that control our internal body clocks.
David Meeker, the former head of rare diseases for Sanofi Genzyme, left the company in 2017 and reappeared at the helm of gene therapy startup KSQ Therapeutics.
Shares of Arbutus Biopharma Corporation shot up after biotech investor Vivek Ramaswamy’s Roivant Sciences upped its stake in the company by $116.4 million to advance that company’s hepatitis B program.
Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.